Roche Hldgs Ag Beare (RHHBF) 280.7500 $RHHBF
Roche On The Wrong Side For Once In Shifting Analyst Forecasts
EP Vantage - Seeking Alpha - Sat Jun 06, 7:32AM CDT
Roche 's ( OTCPK:RHHBF ) ( OTCQX:RHHBY ) reputation as a peerless R&D powerhouse has taken a battering in the past year, and as a consequence, two of its abandoned projects have made the list of top downgrades of the past 12 months. On the...
SGYP: 9.13 (+0.49), VRTX: 122.95 (+2.06), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), IBB: 372.80 (+6.06), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
The Battle Of The Bulge
The Nattering Naybob - at Seeking Alpha - Mon May 18, 8:59AM CDT
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), SYY: 36.05 (+0.05), LO: 71.40 (-0.33), LLY: 88.29 (+0.81), MDRX: 13.25 (+0.22), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), MO: 51.31 (+0.36), ATHN: 114.53 (+0.63), PM: 82.16 (+0.92), JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), AAC: 42.41 (-1.20), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), WTW: 3.97 (+0.19), NVS: 103.22 (+3.20)
The Weekender
Aviate - at Seeking Alpha - Sun May 17, 7:39AM CDT
Rising rates, banks, beta and the pain trade We note a strategy piece by a well-respected strategist this week (JPMorgan) used the word ' reflation ' - one all but removed from investment parlance - with respect to the bond market's rather vicious...
WMT: 73.12 (+0.34), RBS: 10.73 (+0.26), SPY: 207.48 (+2.58), LYG: 5.28 (+0.12), AV: 16.38 (+0.41), MR: 26.11 (+0.38), PSO: 19.11 (+0.56), LBTYK: 47.78 (+1.54), TI: 13.19 (+0.48), LBTYA: 50.86 (+1.87), BHP: 39.47 (+1.07), TEF: 14.62 (+0.87), DIA: 177.41 (+2.15), ING: 16.98 (+1.00), RIO: 39.14 (+0.61), PHG: 26.26 (+1.11), VOD: 36.46 (+1.07), QQQ: 107.65 (+1.62)
Novartis Sees Past Lucentis's Decline
EP Vantage - Seeking Alpha - Wed Mar 04, 9:21AM CST
Having been outmanoeuvred first on price and then on dosing, Novartis (NYSE: NVS ) is preparing its next line of defence in macular degeneration as sales of its flagship Lucentis plateau. A phase II trial has shown that RTH258 is the equal of ...
REGN: 526.01 (+16.98), NVS: 103.22 (+3.20)
TiGenix: Locked And Loaded For Phase 3 Readout
Logribel Biostocks - at Seeking Alpha - Mon Mar 02, 11:30AM CST
GRFS: 31.28 (+0.47), NVS: 103.22 (+3.20)
Flexus Shows Other Immuno-Oncology Wannabes How It's Done
EP Vantage - Seeking Alpha - Wed Feb 25, 1:28PM CST
Deal making in the immuno-oncology space was always going to be a big theme of 2015, and Bristol-Myers Squibb ’s (NYSE: BMY ) moves yesterday – most notably the $800m it paid to secure Flexus Biosciences ’ preclinical...
MRK: 57.95 (+0.57), INCY: 108.33 (+0.22), NLNK: 46.82 (+2.23), BMY: 69.27 (+1.38)
Why Don't You Diversify Your Portfolio With Some European Blue Chips?
Gold Finder - at Seeking Alpha - Fri Jan 23, 9:50AM CST
UN: 43.87 (+2.14), HSBC: 43.87 (+0.85), GOOG: 530.13 (+9.45), T: 34.65 (+0.26), BRK.A: 209,800.00 (+2,060.00), NVS: 103.22 (+3.20)
Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 33.17 (+0.82), AKER: 4.49 (+0.39), WX: 40.50 (+0.96)
Roche On The Wrong Side For Once In Shifting Analyst Forecasts
EP Vantage - Seeking Alpha - Sat Jun 06, 7:32AM CDT
Roche 's ( OTCPK:RHHBF ) ( OTCQX:RHHBY ) reputation as a peerless R&D powerhouse has taken a battering in the past year, and as a consequence, two of its abandoned projects have made the list of top downgrades of the past 12 months. On the...
SGYP: 9.13 (+0.49), VRTX: 122.95 (+2.06), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), IBB: 372.80 (+6.06), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
The Battle Of The Bulge
The Nattering Naybob - at Seeking Alpha - Mon May 18, 8:59AM CDT
ABT: 49.93 (+0.74), PFE: 34.36 (+0.50), SYY: 36.05 (+0.05), LO: 71.40 (-0.33), LLY: 88.29 (+0.81), MDRX: 13.25 (+0.22), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), MO: 51.31 (+0.36), ATHN: 114.53 (+0.63), PM: 82.16 (+0.92), JNJ: 99.53 (+1.13), GILD: 113.74 (+0.38), AAC: 42.41 (-1.20), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), WTW: 3.97 (+0.19), NVS: 103.22 (+3.20)
The Weekender
Aviate - at Seeking Alpha - Sun May 17, 7:39AM CDT
Rising rates, banks, beta and the pain trade We note a strategy piece by a well-respected strategist this week (JPMorgan) used the word ' reflation ' - one all but removed from investment parlance - with respect to the bond market's rather vicious...
WMT: 73.12 (+0.34), RBS: 10.73 (+0.26), SPY: 207.48 (+2.58), LYG: 5.28 (+0.12), AV: 16.38 (+0.41), MR: 26.11 (+0.38), PSO: 19.11 (+0.56), LBTYK: 47.78 (+1.54), TI: 13.19 (+0.48), LBTYA: 50.86 (+1.87), BHP: 39.47 (+1.07), TEF: 14.62 (+0.87), DIA: 177.41 (+2.15), ING: 16.98 (+1.00), RIO: 39.14 (+0.61), PHG: 26.26 (+1.11), VOD: 36.46 (+1.07), QQQ: 107.65 (+1.62)
Novartis Sees Past Lucentis's Decline
EP Vantage - Seeking Alpha - Wed Mar 04, 9:21AM CST
Having been outmanoeuvred first on price and then on dosing, Novartis (NYSE: NVS ) is preparing its next line of defence in macular degeneration as sales of its flagship Lucentis plateau. A phase II trial has shown that RTH258 is the equal of ...
REGN: 526.01 (+16.98), NVS: 103.22 (+3.20)
TiGenix: Locked And Loaded For Phase 3 Readout
Logribel Biostocks - at Seeking Alpha - Mon Mar 02, 11:30AM CST
GRFS: 31.28 (+0.47), NVS: 103.22 (+3.20)
Flexus Shows Other Immuno-Oncology Wannabes How It's Done
EP Vantage - Seeking Alpha - Wed Feb 25, 1:28PM CST
Deal making in the immuno-oncology space was always going to be a big theme of 2015, and Bristol-Myers Squibb ’s (NYSE: BMY ) moves yesterday – most notably the $800m it paid to secure Flexus Biosciences ’ preclinical...
MRK: 57.95 (+0.57), INCY: 108.33 (+0.22), NLNK: 46.82 (+2.23), BMY: 69.27 (+1.38)
Why Don't You Diversify Your Portfolio With Some European Blue Chips?
Gold Finder - at Seeking Alpha - Fri Jan 23, 9:50AM CST
UN: 43.87 (+2.14), HSBC: 43.87 (+0.85), GOOG: 530.13 (+9.45), T: 34.65 (+0.26), BRK.A: 209,800.00 (+2,060.00), NVS: 103.22 (+3.20)
Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 33.17 (+0.82), AKER: 4.49 (+0.39), WX: 40.50 (+0.96)
